{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:09:45Z","timestamp":1790888985013,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006696","name":"Fondazione Guido Berlucchi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC IG22835"],"award-info":[{"award-number":["AIRC IG22835"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Elucidation of the molecular mechanism underlying metastatic dissemination in patients with high-grade serous ovarian carcinoma (HG-SOC) has the potential to affect patient outcome. This study explores the role of gasdermins (GSDMs) in HG-SOC, focusing on novel pyroptosis-independent nuclear functions of GSDME, which are integrated with the endothelin-1 (ET-1)\/ET-1 receptor A (ET\n                    <jats:sub>A<\/jats:sub>\n                    R) signaling to sustain metastatic progression. In this tumor, GSDME upregulation is correlated to epithelial-mesenchymal transition (EMT) and ET\n                    <jats:sub>A<\/jats:sub>\n                    R expression. ET-1 signaling fuels GSDME expression by inducing its transcription via the core EMT factors, ZEB1 and ZEB2. GSDME, in turn, translocates to the nucleus to engage ZEB1 and transcriptionally regulate genes coupled with EMT and inflammatory signals, such as E-cadherin, vimentin and interleukin (IL)-6. GSDME depletion, similarly to ZEB1 and ET\n                    <jats:sub>A<\/jats:sub>\n                    R blockade, restrains ET-1-induced EMT phenotypic plasticity and inflammatory cytokine release. Clinically relevant, ET-1 receptor (ET-1R) antagonist, by depleting the nuclear reservoir of the GSDME\/ZEB1 transcriptional complex, hinders the metastatic traits of HG-SOC. The intertwined ET\n                    <jats:sub>A<\/jats:sub>\n                    R\/GSDME\/ZEB1 circuitry characterizes mesenchymal HG-SOC patients and associates with a high-risk of poor survival. Together, these findings unveil GSDME as a key transcriptional regulator of aggressive behaviors and worse prognosis in HG-SOC patients, in an ET-1-driven alliance with ZEB1, which could be targeted by ET-1R antagonist to reduce the metastatic burden of this tumor.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08202-x","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:25:27Z","timestamp":1768573527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nuclear gasdermin E drives endothelin-1-induced metastatic progression independently of the pyroptosis"],"prefix":"10.1038","volume":"17","author":[{"given":"Celia","family":"Roman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Caprara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-013X","authenticated-orcid":false,"given":"Piera","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-0438","authenticated-orcid":false,"given":"Andrea","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-2241","authenticated-orcid":false,"given":"Giovanni","family":"Blandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7269-9522","authenticated-orcid":false,"given":"Anna","family":"Bagnato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-2777","authenticated-orcid":false,"given":"Rosanna","family":"Sestito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"8202_CR1","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198\u2013208.","journal-title":"Clin Cancer Res"},{"key":"8202_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"8202_CR3","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"8202_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174013","volume":"134","author":"Y Wang","year":"2024","unstructured":"Wang Y, Duval AJ, Adli M, Matei D. Biology-driven therapy advances in high-grade serous ovarian cancer. J Clin Invest. 2024;134:e174013.","journal-title":"J Clin Invest"},{"key":"8202_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/genes12071103","volume":"12","author":"MH Sohn","year":"2021","unstructured":"Sohn MH, Kim SI, Shin JY, Kim HS, Chung HH, Kim JW, et al. Classification of high-grade serous ovarian carcinoma by epithelial-to-mesenchymal transition signature and homologous recombination repair genes. Genes. 2021;12:1103.","journal-title":"Genes"},{"key":"8202_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/emmm.200900043","volume":"1","author":"JM L\u00f3pez-Novoa","year":"2009","unstructured":"L\u00f3pez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1:303\u201314.","journal-title":"EMBO Mol Med"},{"key":"8202_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/1878-0261.12095","volume":"11","author":"M Suarez-Carmona","year":"2017","unstructured":"Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 2017;11:805\u201323.","journal-title":"Mol Oncol"},{"key":"8202_CR8","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40:e108647.","journal-title":"EMBO J"},{"key":"8202_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.15698\/cst2017.12.117","volume":"1","author":"M Diepenbruck","year":"2017","unstructured":"Diepenbruck M, Christofori G. Reciprocal regulatory circuits coordinating EMT plasticity. Cell Stress. 2017;1:139\u201340.","journal-title":"Cell Stress"},{"key":"8202_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1042\/CS20240426","volume":"138","author":"PF Arndt","year":"2024","unstructured":"Arndt PF, Turkowski K, Cekay MJ, Eul B, Grimminger F, Savai R. Endothelin and the tumor microenvironment: a finger in every pie. Clin Sci. 2024;138:617\u201334.","journal-title":"Clin Sci"},{"key":"8202_CR11","doi-asserted-by":"publisher","first-page":"11649","DOI":"10.1158\/0008-5472.CAN-05-2123","volume":"65","author":"L Rosan\u00f2","year":"2005","unstructured":"Rosan\u00f2 L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 2005;65:11649\u201357.","journal-title":"Cancer Res"},{"key":"8202_CR12","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1158\/1078-0432.CCR-10-2325","volume":"17","author":"L Rosan\u00f2","year":"2011","unstructured":"Rosan\u00f2 L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17:2350\u201360.","journal-title":"Clin Cancer Res"},{"key":"8202_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc3546","volume":"13","author":"L Rosan\u00f2","year":"2013","unstructured":"Rosan\u00f2 L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013;13:637\u201351.","journal-title":"Nat Rev Cancer"},{"key":"8202_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s42003-020-01404-3","volume":"3","author":"R Sestito","year":"2020","unstructured":"Sestito R, Cianfrocca R, Tocci P, Rosan\u00f2 L, Sacconi A, Blandino G, et al. Targeting endothelin 1 receptor-miR-200b\/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. Commun Biol. 2020;3:677.","journal-title":"Commun Biol"},{"key":"8202_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13046-022-02317-1","volume":"41","author":"R Sestito","year":"2022","unstructured":"Sestito R, Tocci P, Roman C, Di Castro V, Bagnato A. Functional interaction between endothelin-1 and ZEB1\/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. J Exp Clin Cancer Res. 2022;41:157.","journal-title":"J Exp Clin Cancer Res"},{"key":"8202_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828303","volume":"12","author":"T Liu","year":"2022","unstructured":"Liu T, Hou M, Li M, Qiu C, Cheng L, Zhu T, et al. Pyroptosis: a developing foreland of ovarian cancer treatment. Front Oncol. 2022;12:828303.","journal-title":"Front Oncol"},{"key":"8202_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06382-y","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Liu Y, Zong L, Zhang W, Liu R, Xing Q, et al. The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles. Cell Death Dis. 2023;14:836.","journal-title":"Cell Death Dis"},{"key":"8202_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216206","volume":"564","author":"S Li","year":"2023","unstructured":"Li S, Yue M, Xu H, Zhang X, Mao T, Quan M, et al. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Cancer Lett. 2023;564:216206.","journal-title":"Cancer Lett"},{"key":"8202_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goae102","volume":"12","author":"Y Lu","year":"2025","unstructured":"Lu Y, Xu J, Lin H, Zhu M, Li M. Gasdermin E mediates pyroptosis in the progression of hepatocellular carcinoma: a double-edged sword. Gastroenterol Rep. (Oxf). 2025;12:goae102.","journal-title":"Gastroenterol Rep. (Oxf)"},{"key":"8202_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-025-00837-0","volume":"26","author":"Y Bai","year":"2025","unstructured":"Bai Y, Pan Y, Liu X. Mechanistic insights into gasdermin-mediated pyroptosis. Nat Rev Mol Cell Biol. 2025;26:501\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8202_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505567","volume":"2","author":"X Yang","year":"2025","unstructured":"Yang X, Xu C, Zeng Y, Wang C, Gao Y, Ding J, et al. Pyroptosis-inducing platinum (IV) prodrugs via GSDME pathway for chemoimmunotherapy and metastasis inhibition in triple-negative breast cancer. Adv Sci (Weinh). 2025;2:e05567.","journal-title":"Adv Sci (Weinh)"},{"key":"8202_CR22","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1038\/s41388-022-02503-7","volume":"41","author":"X Peng","year":"2022","unstructured":"Peng X, Na R, Zhou W, Meng X, Yang Y, Amini S, et al. Nuclear translocation of Gasdermin D sensitizes colorectal cancer to chemotherapy in a pyroptosis-independent manner. Oncogene. 2022;41:5092\u2013106.","journal-title":"Oncogene"},{"key":"8202_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41556-022-00857-4","volume":"24","author":"J Lv","year":"2022","unstructured":"Lv J, Liu Y, Mo S, Zhou Y, Chen F, Cheng F, et al. Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1-mucin pathway. Nat Cell Biol. 2022;24:364\u201372.","journal-title":"Nat Cell Biol"},{"key":"8202_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308990","volume":"11","author":"R Wu","year":"2024","unstructured":"Wu R, Li J, Aicher A, Jiang K, Tondi S, Dong S, et al. Gasdermin C promotes stemness and immune evasion in pancreatic cancer via pyroptosis-independent mechanism. Adv Sci (Weinh). 2024;11:e2308990.","journal-title":"Adv Sci (Weinh)"},{"key":"8202_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.781365","volume":"9","author":"C Jia","year":"2021","unstructured":"Jia C, Zhang Z, Tang J, Cai MC, Zang J, Shi K, et al. Epithelial-mesenchymal transition induces GSDME transcriptional activation for inflammatory pyroptosis. Front Cell Dev Biol. 2021;9:781365.","journal-title":"Front Cell Dev Biol"},{"key":"8202_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15348-7","volume":"12","author":"T Kobayashi","year":"2022","unstructured":"Kobayashi T, Mitsuhashi A, Hongying P, Shioya M, Kojima K, Nishikimi K, et al. Bexarotene-induced cell death in ovarian cancer cells through caspase-4-gasdermin E mediated pyroptosis. Sci Rep. 2022;12:11123.","journal-title":"Sci Rep"},{"key":"8202_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114529","volume":"161","author":"C Yang","year":"2023","unstructured":"Yang C, Wang ZQ, Zhang ZC, Lou G, Jin WL. CBL0137 activates ROS\/BAX signaling to promote caspase-3\/GSDME-dependent pyroptosis in ovarian cancer cells. Biomed Pharmacother. 2023;161:114529.","journal-title":"Biomed Pharmacother"},{"key":"8202_CR28","doi-asserted-by":"publisher","first-page":"e009032","DOI":"10.1136\/jitc-2024-009032","volume":"12","author":"Y Xia","year":"2024","unstructured":"Xia Y, Huang P, Qian YY, Wang Z, Jin N, Li X, et al. PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD\/E axis in ovarian cancer. J Immunother Cancer. 2024;12:e009032.","journal-title":"J Immunother Cancer"},{"key":"8202_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116695","volume":"232","author":"D Zhang","year":"2025","unstructured":"Zhang D, Chen Y, Sun Y, Xu H, Wei R, Zhou Y, et al. Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS\/p53\/mitochondria\/caspase-3 in ovarian cancer cells. Biochem Pharm. 2025;232:116695.","journal-title":"Biochem Pharm"},{"key":"8202_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11045-8","volume":"10","author":"P Tocci","year":"2019","unstructured":"Tocci P, Cianfrocca R, Di Castro V, Rosan\u00f2 L, Sacconi A, Donzelli S, et al. \u03b2-arrestin1\/YAP\/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. Nat Commun. 2019;10:3196.","journal-title":"Nat Commun"},{"key":"8202_CR31","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1093\/emboj\/16.13.3935","volume":"16","author":"A Postigo","year":"1997","unstructured":"Postigo A, Dean DC. ZEB, a vertebrate homolog of Drosophila Zfh-1, is a negative regulator of muscle differentiation. EMBO J. 1997;16:3935\u201343.","journal-title":"EMBO J"},{"key":"8202_CR32","doi-asserted-by":"publisher","first-page":"20489","DOI":"10.1074\/jbc.274.29.20489","volume":"274","author":"K Verschueren","year":"1999","unstructured":"Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, et al. SIP1, a novel zinc finger\/homeodomain repressor, interacts with Smad proteins and binds to 5\u2019-CACCT sequences in candidate target genes. J Biol Chem. 1999;274:20489\u201398.","journal-title":"J Biol Chem"},{"key":"8202_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05612-7","volume":"14","author":"I Masi","year":"2023","unstructured":"Masi I, Ottavi F, Del Rio D, Caprara V, Vastarelli C, Giannitelli SM, et al. The interaction of \u03b2-arrestin1 with talin1 driven by endothelin A receptor as a feature of \u03b15\u03b21 integrin activation in high-grade serous ovarian cancer. Cell Death Dis. 2023;14:73.","journal-title":"Cell Death Dis"},{"key":"8202_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"8202_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41416-020-01178-9","volume":"124","author":"SV Vasaikar","year":"2021","unstructured":"Vasaikar SV, Deshmukh AP, den Hollander P, Addanki S, Kuburich NA, Kudaravalli S, et al. EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. Br J Cancer. 2021;124:259\u201369.","journal-title":"Br J Cancer"},{"key":"8202_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"8202_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"8202_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121058","volume":"276","author":"S Son","year":"2021","unstructured":"Son S, Shin JM, Shin S, Kim CH, Lee JA, Ko H, et al. Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade. Biomaterials. 2021;276:121058.","journal-title":"Biomaterials"},{"key":"8202_CR39","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.7150\/thno.68864","volume":"12","author":"CH Lee","year":"2022","unstructured":"Lee CH, Bae JH, Choe EJ, Park JM, Park SS, Cho HJ, et al. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1. Theranostics. 2022;12:1971\u201387.","journal-title":"Theranostics"},{"key":"8202_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05538-6","volume":"14","author":"P Tocci","year":"2023","unstructured":"Tocci P, Roman C, Sestito R, Di Castro V, Sacconi A, Molineris I, et al. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition. Cell Death Dis. 2023;14:5.","journal-title":"Cell Death Dis"},{"key":"8202_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1531695","volume":"16","author":"S He","year":"2025","unstructured":"He S, Huang Q, Cheng J. The conflicting role highlights the complexity of GSDMs in cancer. Front Immunol. 2025;16:1531695.","journal-title":"Front Immunol"},{"key":"8202_CR42","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1541-7786.MCR-19-0380","volume":"17","author":"HJ Cho","year":"2019","unstructured":"Cho HJ, Oh N, Park JH, Kim KS, Kim HK, Lee E, et al. ZEB1 collaborates with ELK3 to repress E-cadherin expression in triple-negative breast cancer cells. Mol Cancer Res. 2019;17:2257\u201366.","journal-title":"Mol Cancer Res"},{"key":"8202_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1042\/CS20240346","volume":"138","author":"P Tocci","year":"2024","unstructured":"Tocci P, Roman C, Sestito R, Caprara V, Sacconi A, Molineris I, et al. The endothelin-1-driven tumor-stroma feed-forward loops in high-grade serous ovarian cancer. Clin Sci (Lond). 2024;138:851\u201362.","journal-title":"Clin Sci (Lond)"},{"key":"8202_CR44","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1136\/gutjnl-2018-317294","volume":"68","author":"O De Barrios","year":"2019","unstructured":"De Barrios O, Sanchez-Moral L, Cort\u00e9s M, Ninfali C, Profit\u00f3s-Pelej\u00e0 N, Mart\u00ednez-Campanario MC, et al. ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells. Gut. 2019;68:2129\u201341.","journal-title":"Gut"},{"key":"8202_CR45","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1038\/s44319-024-00186-7","volume":"25","author":"C Menche","year":"2024","unstructured":"Menche C, Schuhwerk H, Armstark I, Gupta P, Fuchs K, van Roey R, et al. ZEB1-mediated fibroblast polarization controls inflammation and sensitivity to immunotherapy in colorectal cancer. EMBO Rep. 2024;25:3406\u201331.","journal-title":"EMBO Rep"},{"key":"8202_CR46","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.3390\/cancers16244187","volume":"16","author":"H Amer","year":"2024","unstructured":"Amer H, Kampan NC, Itsiopoulos C, Flanagan KL, Scott CL, Kartikasari AER, et al. Interleukin-6 modulation in ovarian cancer necessitates a targeted strategy: from the approved to emerging therapies. Cancers (Basel). 2024;16:4187.","journal-title":"Cancers (Basel)"},{"key":"8202_CR47","doi-asserted-by":"publisher","unstructured":"Jonckheere S, Taminau J, Adams J, Haerinck J, De Coninck J, Verstappe J, et al. Development and validation of a high-throughput screening pipeline of compound libraries to target EMT. Cell Death Differ. 2025. https:\/\/doi.org\/10.1038\/s41418-025-01515-6.","DOI":"10.1038\/s41418-025-01515-6"},{"key":"8202_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01083-7","volume":"21","author":"L Xu","year":"2023","unstructured":"Xu L, Shi F, Wu Y, Yao S, Wang Y, Jiang X, et al. Gasdermin E regulates the stability and activation of EGFR in human non-small cell lung cancer cells. Cell Commun Signal. 2023;21:83.","journal-title":"Cell Commun Signal"},{"key":"8202_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06545-5","volume":"15","author":"F Long","year":"2024","unstructured":"Long F, Wei X, Chen Y, Li M, Lian N, Yu S, et al. Gasdermin E promotes translocation of p65 and c-jun into nucleus in keratinocytes for progression of psoriatic skin inflammation. Cell Death Dis. 2024;15:180.","journal-title":"Cell Death Dis"},{"key":"8202_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-023-01192-4","volume":"16","author":"P Kumar","year":"2023","unstructured":"Kumar P, Ranmale S, Mehta S, Tongaonkar H, Patel V, Singh AK, et al. Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer. J Ovarian Res. 2023;16:114.","journal-title":"J Ovarian Res"},{"key":"8202_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2327-1","volume":"11","author":"J Meng","year":"2020","unstructured":"Meng J, Liu K, Shao Y, Feng X, Ji Z, Chang B, et al. ID1 confers cancer cell chemoresistance through STAT3\/ATF6-mediated induction of autophagy. Cell Death Dis. 2020;11:137.","journal-title":"Cell Death Dis"},{"key":"8202_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1511-7","volume":"15","author":"D Lane","year":"2015","unstructured":"Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015;15:492.","journal-title":"BMC Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08202-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:03:01Z","timestamp":1768579381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08202-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8202"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08202-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol for ascitic sample collection and clinical information was performed in accordance with the Declaration of Helsinki and was approved by the IRCCS-Regina Elena National Cancer Institute institutional review board. Patient provided written informed consent to authorize the collection and use of the sample employed in this study. Procedures involving animals and their care were conducted with the permission from the IRCCS Regina Elena Cancer Institute Animal Care and Use Committee and the Italian Ministry of Health (D.lgs 26\/2014, authorization number 1083\/2020PR, issued 5 November 2020 by Ministero della Salute). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"45"}}